CLAIM AMENDMENTS

1. (amended)A transgenic mouse whose genome comprises

a transgene comprising ~~a transcriptional control region~~ SM22α promoter operably linked to a cDNA encoding a calreticulin (CRT) peptide, said peptide having at least 60% homology to SEQ ID No. 23, ~~wherein said control region comprises a promoter~~

wherein expression of calreticulin from the SM22α promoter in the vascular smooth muscle cells of the transgenic mouse results in hemangioma formation.

2. cancelled.

3. (amended)A transgene comprising ~~a transcriptional control region~~ SM22α promoter operably linked to a cDNA encoding a calreticulin peptide, said peptide having at least 60% homology to SEQ ID No. 23~~wherein said control region comprises a SM22α promoter~~.

4. (amended)A method for producing a transgenic mouse having symptoms similar to hemangioendothelioma ~~whose genome comprises CRT~~ comprising:

introducing into a fertilized mouse egg a transgene comprising SM22α promoter ~~a transcriptional control region~~ operably linked to a cDNA encoding ~~CRT~~ a calreticulin (CRT) peptide, said peptide having at least 60% homology to SEQ ID No. 23 ~~wherein said control region comprises a promoter~~;

transplanting the injected egg in a foster parent female mouse; and

selecting a mouse derived from an injected egg whose genome comprises ~~CRT~~SM22α promoter operably linked to a cDNA encoding a calreticulin peptide, said peptide having at least 60% homology to SEQ ID No. 23,

wherein expression of calreticulin from the SM22α promoter in the vascular smooth muscle cells of the transgenic mouse results in hemangioma formation.

5. cancelled.

6. (withdrawn) A method for screening compounds that inhibit vascular tumor formation in a transgenic mouse comprising

providing a transgenic mouse whose genome comprises a transgene comprising a transcriptional control region operably linked to a cDNA encoding

calreticulin (CRT);

allowing CRT to be expressed in said transgenic mouse

administering a compound to said mouse; and

determining whether said compound reduces hemangioma formation.

7. (withdrawn) A compound isolated according to the method of claim 6.

8. (withdrawn) A method of testing the therapeutic activity of a pharmacological agent on Kaposiform hemangioenothelioma comprising administering an effective amount of said pharmacological agent to the mouse of claim 1 and evaluating said agent's effect on hemangioma formation of said mouse.

9. (withdrawn) A compound isolated according to the method of claim 8.

10. (withdrawn) A method of inhibiting hemangioma formation comprising administering an effective amount of a matrix metalloproteinase inhibitor to a patient in need of such treatment.

11. (withdrawn) A method of inhibiting hemangioma comprising administering to an individual in need of such treatment an effective amount of virally-administered small interference RNA (siRNA) corresponding to a portion of CRT mRNA, wherein expression of the siRNA decreases the level of CRT.

12. (new) The transgenic mouse according to claim 1 wherein the CRT peptide is at least 70% homologous to SEQ ID No. 23.

13. (new) The transgenic mouse according to claim 1 wherein the CRT peptide is at least 80% homologous to SEQ ID No. 23.

14. (new) The transgenic mouse according to claim 1 wherein the SM22α promoter is a DNA sequence corresponding to nucleotides 1 to 1343 of SEQ ID No. 1.

15. (new) The transgenic mouse according to claim 4 wherein the CRT peptide is at least 70% homologous to SEQ ID No. 23.

16. (new) The method according to claim 4 wherein the CRT peptide is at least 80% homologous to SEQ ID No. 23.

17. (new) The method according to claim 4 wherein the SM22α promoter is a DNA sequence corresponding to nucleotides 1 to 1343 of SEQ ID No. 1.

18. (new) The transgene according to claim 3 wherein the transgene is a

DNA sequence corresponding to nucleotides 1 to 2655 of SEQ ID No. 1.

19. (new) The transgene according to claim 3 wherein the transgene is a DNA sequence corresponding to nucleotides 1 to 2691 of SEQ ID No. 12.